Abstract 2093P
Background
The combination treatment of paclitaxel plus ramucirumab [PACL(W)+RAMU] is a widely accepted option for advanced gastric cancer (AGC) as a second-line chemotherapy to prolong survival. The aim of the study is to identify the validity of bioelectrical impedance analysis (BIA) as a prognosticator in patients receiving PACL(W)+RAMU treatment.
Methods
The study population comprised 189 patients who received PACL(W)+RAMU between Oct. 2019 and Nov. 2022. BIA was conducted at baseline of the PACL(W)+RAMU treatment on all patients and whole body PhA was derived. Continuous variables of other body compartment and blood biochemical values (including complete blood count, serum electrolytes and chemistry) were dichotomized according to the best cut-off values determined by the Contal and O’Quigley methods or the normal values. Kaplan-Meier method and the Cox proportional hazard model were constructed to evaluate the prognostic effect the body component.
Results
Median age of the patients was 59. The cut-off value of PhA was determined as 4.6⁰ at 50 kHz. Median overall survival (OS) of the lower PhA group was 38 weeks (95% CI, 32-45) and 52 weeks (95% CI, 39∼65) for higher PhA group (P=0.021). When combining PhA with obesity degree (current weight/target weight x 100), high phA and low obesity degree (< 116%) demonstrated the favorable OS of 54 weeks (95% CI, 40-68), which contrasts to only 14 weeks (95% CI, 10-18) for low PhA and high obesity degree (≥ 116%) group. In multivariate analysis, the PhA combined with obesity degree is an independent prognosticator for OS (hazard ratio [HR], 6.506 for low PhA and high obesity degree, 95% CI, 3.237-13.076, P<0.001) along with neutrophil-to-lymphocyte ratio and extracellular water.
Conclusions
Bioelectrical impedance component and phase angle could be a useful prognosticator for patients with metastatic gastric cancer. Larger sample size and independent set will be needed to further validate the significance of this study in palliative cancer treatment settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06